[HTML][HTML] Monitoring chronic myeloid leukemia patients responding to treatment with tyrosine kinase inhibitors by real-time quantitative polymerase chain reaction
Introduction: Historically, many revolutionary advances in therapy for chronic myeloid
leukemia (CML) have been achieved over time, among them most important being imatinib …
leukemia (CML) have been achieved over time, among them most important being imatinib …
Monitoring chronic myeloid leukemia patients responding to treatment with tyrosine kinase inhibitors by real-time quantitative polymerase chain reaction
Sažetak Introduction: Historically, many revolutionary advances in therapy for chronic
myeloid leukemia (CML) have been achieved over time, among them most important being …
myeloid leukemia (CML) have been achieved over time, among them most important being …
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors with real-time quantitative polymerase chain reaction
Sažetak Historically, chronic myeloid leukemia (CML) had many revolutional advances in
therapy implementation. Discovery of new improved drugs like imatinib mesylate (IM) …
therapy implementation. Discovery of new improved drugs like imatinib mesylate (IM) …
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with …
B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann… - Leukemia, 2014 - nature.com
Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become
an important tool to predict favorable outcome. We sought to investigate the impact of …
an important tool to predict favorable outcome. We sought to investigate the impact of …
[HTML][HTML] Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
M Serpa, SS Sanabani, PE Dorliac-Llacer, M Conchon… - BMC Hematology, 2010 - Springer
Background The monitoring of BCR-ABL transcript levels by real-time quantitative
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
Early molecular response in chronic myeloid leukemia patients predicts future response status
S Kagita, S Jiwtani, S Uppalapati, VG Linga, S Gundeti… - Tumor Biology, 2014 - Springer
Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management. Most of
the CML patients achieve major responses, but a proportion (nearly 25–35%) of them …
the CML patients achieve major responses, but a proportion (nearly 25–35%) of them …
[HTML][HTML] Harmonization of Molecular Monitoring of CML Therapy in Europe–Perspective of Widespread Competence in BCR-ABL Quantification.
MC Müller, NCP Cross, P Erben, T Schenk, T Ernst… - Blood, 2009 - Elsevier
Abstract Abstract 2616 Poster Board II-592 Introduction: The high efficacy of standard
treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for …
treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for …
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib
SL Goldberg, L Chen, A Guerin… - … medical research and …, 2013 - Taylor & Francis
Objective: Molecular monitoring using quantitative polymerase chain reaction (qPCR) of
BCR-ABL mRNA transcripts using the international scale (IS) is recommended by the …
BCR-ABL mRNA transcripts using the international scale (IS) is recommended by the …
Harmonization of molecular monitoring of CML therapy in Europe
MC Müller, NCP Cross, P Erben, T Schenk, B Hanfstein… - Leukemia, 2009 - nature.com
The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib
has prompted the need for accurate methods to monitor response at levels below the …
has prompted the need for accurate methods to monitor response at levels below the …
Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia
The optimal management of malignant haematological disorders depend on the degree of
tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for …
tumor load reduction after therapy. Chronic myeloid leukemia constitutes a clinical model for …